Møller P - Search Results

1

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.

Dørum A, Heimdal K, Hovig E, Inganäs M, Møller P. Dørum A, et al. Among authors: moller p. Am J Hum Genet. 1999 Sep;65(3):671-9. doi: 10.1086/302530. Am J Hum Genet. 1999. PMID: 10441573 Free PMC article.

2

The problem of skipped generation and subclinical disease in familial breast-ovarian cancer.

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P. Dørum A, et al. Among authors: moller p. Acta Obstet Gynecol Scand. 1997 Feb;76(2):166-8. doi: 10.3109/00016349709050074. Acta Obstet Gynecol Scand. 1997. PMID: 9049291 Free article.

3

Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL. Andersen TI, et al. Among authors: moller p. Hum Mutat. 1998;11(2):166-74. doi: 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X. Hum Mutat. 1998. PMID: 9482581

4

Clinical implications of BRCA1 genetic testing.

Dørum A, Heimdal K, Møller P. Dørum A, et al. Among authors: moller p. Acta Obstet Gynecol Scand. 1998 Apr;77(4):458-61. Acta Obstet Gynecol Scand. 1998. PMID: 9598958 No abstract available.

5

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ. Dørum A, et al. Among authors: moller p. Eur J Cancer. 1997 Dec;33(14):2390-2. doi: 10.1016/s0959-8049(97)00328-6. Eur J Cancer. 1997. PMID: 9616287

6

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.

Dørum A, Hovig E, Tropé C, Inganas M, Møller P. Dørum A, et al. Among authors: moller p. Eur J Cancer. 1999 May;35(5):779-81. doi: 10.1016/s0959-8049(99)00050-7. Eur J Cancer. 1999. PMID: 10505039

7

[Hereditary breast cancer in Norway].

Heimdal K, Apold J, Maehle L, Dørum A, Møller P. Heimdal K, et al. Among authors: moller p. Tidsskr Nor Laegeforen. 1999 Oct 30;119(26):3929-32. Tidsskr Nor Laegeforen. 1999. PMID: 10592755 Review. Norwegian.

8

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P. Borg A, et al. Among authors: moller p. Dis Markers. 1999 Oct;15(1-3):79-84. doi: 10.1155/1999/278269. Dis Markers. 1999. PMID: 10595257 Free PMC article.

9

Costs and benefits of diagnosing familial breast cancer.

Heimdal K, Maehle L, Møller P. Heimdal K, et al. Among authors: moller p. Dis Markers. 1999 Oct;15(1-3):167-73. doi: 10.1155/1999/751892. Dis Markers. 1999. PMID: 10595273 Free PMC article.

10

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.

Møller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L; Norwegian Inherited Breast Cancer Group; Norwegian Inherited Ovarian Cancer Group. Møller P, et al. Eur J Cancer. 2001 May;37(8):1027-32. doi: 10.1016/s0959-8049(01)00075-2. Eur J Cancer. 2001. PMID: 11334729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,947 results

Search Page